ML-T7

• CAT Number: I040149
• CAS Number: 459789-75-4
• Molecular Formula: C27H17Cl2NO5
• Molecular Weight: 506.33
• Purity: ≥95%
• Synonyms: 5-(2,4-dichlorophenyl)-1-(4-methylphenyl)spiro[3a,6a-dihydro-1H-furo[3,4-c]pyrrole-3,2′-indene]-1′,3′,4,6-tetrone
• InChI: InChI=1S/C27H17Cl2NO5/c1-13-6-8-14(9-7-13)22-20-21(26(34)30(25(20)33)19-11-10-15(28)12-18(19)29)27(35-22)23(31)16-4-2-3-5-17(16)24(27)32/h2-12,20-22H,1H3
• InChIKey: OFJOQMMYCMPPEC-UHFFFAOYSA-N
• SMILES: CC1=CC=C(C=C1)C2C3C(C(=O)N(C3=O)C4=C(C=C(C=C4)Cl)Cl)C5(O2)C(=O)C6=CC=CC=C6C5=O

ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1.
ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research[1].
ML-T7(10 μM, 0-6 days) enhances TCR/STAT5 signaling and promotes CD8+ cell antitumor activity through Tim-3[1].
ML-T7(10 μM, 24 h) promotes DC maturation and function through Tim-3 and Tim-4, enhances DC antigen-presenting ability[1].
ML-T7(10 μM, 24 h) enhances CTL activation and cytokine production, decreases apoptosis of CTLs[1].
ML-T7(10 μM, 48 h) significantly enhances the production of IFN-γ, TNF-α, CD107a, and granzyme B in human NK cell line NK92 cells[1].
ML-T7 (10-50 mg/kg; Intraperitoneal injection; every 2 days, 10 times) inhibits the growth of tumor and prolongs survival of HCC mice, without adverse effects on mice body weight[1].
ML-T7 (20 mg/kg; Intraperitoneal injection; every 2 days, 10 times) synergizes with Nivolumab (HY-P9903A) to improve the antitumor efficacy of Nivolumab (HY-P9903A) antibodies, and effectively improves HCC mice survival[1].
ML-T7 (50 mg/kg, Intraperitoneal injection; every 2 days for 3 weeks)shows a good safety profile in mice[1].

Reference

[1]. Ma S, et al. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med. 2023 Nov 15;15(722):eadg6752.
 [Content Brief]